Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASALTS:0RAM -1.47%77 Days Sales Outstanding is 77.20 as of Mar. 2026, which is 47% above its 10-year median of 52.67. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.78 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 948 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 52.74% on this metric.
The historical rank and industry rank for Vistin Pharma ASA's Days Sales Outstanding or its related term are showing as below:
LTS:0RAM'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.83 Med: 52.67 Max: 105.92
Current: 69.39
During the past 13 years, Vistin Pharma ASA's highest Days Sales Outstanding was 105.92. The lowest was 38.83. And the median was 52.67.
LTS:0RAM's Days Sales Outstanding is ranked better than 52.74% of 948
companies
in the Drug Manufacturers industry
Industry Median: 71.99
vs LTS:0RAM: 69.39
Vistin Pharma ASA's Days Sales Outstanding
increased
from Mar. 2025 (44.16) to Mar. 2026 (77.20).
Vistin Pharma ASA (LTS:0RAM) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Vistin Pharma ASA Days Sales Outstanding Related Terms
Vistin Pharma ASA Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Days Sales Outstanding falls into.
Vistin Pharma ASA Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (LTS:0RAM) has a Days Sales Outstanding of 77.20 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vistin Pharma ASA and its competitors. This is 47% above median its historical median of 52.67. Over the past decade, Vistin Pharma ASA's Days Sales Outstanding has ranged from 38.83 to 105.92. According to the industry distribution chart, Vistin Pharma ASA ranks #448 out of 948 companies in the Drug Manufacturers industry, placing it in the top 47.3%.
Is Vistin Pharma ASA's Days Sales Outstanding too high?
Vistin Pharma ASA's current Days Sales Outstanding of 77.20 is 47% above median its 10-year median of 52.67. Over the past 10 years, this metric has ranged from a low of 38.83 to a high of 105.92. The Drug Manufacturers industry median Days Sales Outstanding is 71.99. Vistin Pharma ASA's value of 77.20 is 7.2% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #448 out of 948 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #448 out of 948 companies for Days Sales Outstanding. This puts Vistin Pharma ASA in the upper half of its industry. The industry median Days Sales Outstanding is 71.99. Vistin Pharma ASA's value of 77.20 is 7.2% above this benchmark. Historically, Vistin Pharma ASA's own Days Sales Outstanding has ranged from 38.83 to 105.92 over the past decade. While the company's 10-year median is 52.67 vs. the industry median of 71.99, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.99, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Days Sales Outstanding of 77.20 is 7.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Days Sales Outstanding is 77.20, which is 47% above median its own 10-year median of 52.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.78, compared to a current price of kr20.10 — trading 22% below its estimated fair value. The current Days Sales Outstanding is 77.20, which is 47% above median its 10-year median of 52.67 and 7.2% above the Drug Manufacturers industry median of 71.99. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Days Sales Outstanding is 77.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.10 is trading 22% below its estimated GF Value™ of kr25.78.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Days Sales Outstanding: 77.20 (47% above median its 10-year median of 52.67)
GF Value™: kr25.78 vs. price of kr20.10 (22% below fair value)
Industry Position: 7.2% above the Drug Manufacturers median (#448 of 948)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
